TERT promoter mutations were also associated with adverse outcomes, including tumor persistence/recurrence (OR, 5.30; 95% CI, 4.19–6.71; P < 0.05) and disease-specific mortality (OR, 8.29; 95% CI, 5.76–11.93; P < 0.05). The gene discussed is TERT; the disease is neoplasm.